ClinicalTrials.gg
RecruitingNCT07210723KINSHIP-DCMUpdated Nov 4, 2026

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

A Phase 2/3 interventional study of danicamtiv and Placebo in Symptomatic Genetic Dilated Cardiomyopathy, sponsored by Kardigan, Inc.. Recruiting at 79 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Kardigan, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 4, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Cardiomyopathy, Dilated with a site in United States — 14 open to participants now, 20 under way, 2 of them phase 3. Cardiomyopathy, Dilated · United States.

Planned enrollment
3rd of 42
332 · median 37
Started
2026
with 4 others
Phase 2/3
Only one
of the 64
Primary completion
2027-09
later than 7 of 19 live
Registered
59th of 64
by date
Lead sponsor
2 of 64
Kardigan, Inc.

Among the 64 studies in Cardiomyopathy, Dilated with a site in United States, this one is the 3rd largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 7 of the 19 other live ones, and was the 59th registered.

Cardiomyopathy, Dilated

255 studies on the registry are indexed under Cardiomyopathy, Dilated; 66 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

14 of the 64 studies in Cardiomyopathy, Dilated with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Cardiomyopathy, Dilated studies recruiting now, 30 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 13 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Cardiomyopathy, Dilated with a site in United States, or all of them as a file.
02

Study summary

The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM.

The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM).

The main goals of the study are:

  • To assess the effect of danicamtiv on cardiac function using echocardiogram.
  • To evaluate the impact of danicamtiv on exercise capacity
  • To evaluate the safety and tolerability of danicamtiv

Participants will:

  • Take danicamtiv or placebo every day for approximately 6 months
  • Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up
03

Conditions studied

  • Symptomatic Genetic Dilated Cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has a diagnosis of DCM due to probable disease-causing variants of MYH7, TTN, or other identified genetic DCM variants, or with familial DCM
  2. Has (NYHA) Class II-IV at Screening with stable symptoms for ≥1 month.
  3. Has at least mild left ventricular enlargement (LVE) and has adequate acoustic windows to enable accurate TTEs according to the Echocardiography Core Laboratory.
  4. Has a of ≤45%.
  5. Is on stable doses of maximally tolerated standard-of-care heart failure (HF) therapies reflecting current guidelines for at least 4 weeks prior to the first visit.
  6. Has DCM not attributed to substance abuse, amyloidosis, sarcoidosis, or any other secondary form of cardiomyopathy per the Investigator.
  7. Can perform an upright cardiopulmonary exercise training (CPET) with a peak oxygen uptake (pV̇O2) of 80% or less of predicted for a healthy individual and respiratory exchange ratio (RER) of ≥1.05

Key Exclusion Criteria:

  1. Has heart failure with reduced ejection (HFrEF) caused primarily by ischemic heart disease, chronic valvulopathy, or another condition, as determined by the Investigator.
  2. Recent (\<90 days) cardiac events, including acute coronary syndrome, hemodynamically significant epicardial coronary disease (per Investigator), coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]), or hospitalization for heart failure/intravenous (IV) diuretic use.
  3. Presence of disqualifying cardiac rhythms that might interfere with reliable echocardiographic measurements of left ventricle (LV) function, as determined by the Investigator including: (a) inadequately rate-controlled atrial fibrillation, (b) ectopic beats (atrial, junctional or ventricular) of sufficient frequency (e.g. > 10% of total beats) that the participant's cardiac rhythm is irregular potentially interfering with reliable echocardiographic measurements of LV function.
  4. Unstable or untreated severe ventricular arrythmia (eg, ventricular tachycardia or ventricular fibrillation).
  5. History of of any type within 5 years prior to Screening
  6. Severe renal insufficiency (defined at the time of Screening as current estimated [eGFR] \<15 mL/min/1.73m2 by simplified Modification of Diet in Renal Disease equation [sMDRD]).
  7. History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the Investigator or Sponsor, would pose a risk to participant safety or interfere with the study evaluation
  8. History of heart transplantation or anticipated heart transplantation in the next 6 months.
  9. Ongoing or anticipated advanced cardiac interventions, including chronic IV inotropic therapy, planned cardiac resynchronization therapy (CRT) or major surgery, or current/anticipated ventricular assist device placement within 6 months
  10. Clinically significant laboratory abnormalities at Screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
332 participants (estimated)

Study arms

  • Experimental
    danicamtiv

    Drug: danicamtiv

  • Placebo comparator
    placebo

    Drug: Placebo

Interventions

  • Danicamtiv will be administrated twice daily for up to 26 weeks

  • DrugPlacebo

    Placebo will be administrated twice daily for up to 26 weeks

06

What researchers measure

Primary outcomes

  1. Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in Cohort 1

    Time frame: 26 weeks

  2. Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in Cohort 1

    Time frame: 26 weeks

Secondary outcomes

  1. Part 1: Change from Baseline (Day 1) to Week 26 in peak VO2

    Time frame: 26 weeks

  2. Part 1: Association between response in left ventricular global longitudinal strain and/or left atrial function index after 2 weeks of active treatment with placebo-adjusted Week 26 response in peak VO2

    Time frame: 26 weeks

  3. Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in overall population

    Time frame: 26 weeks

  4. Part 1 and 2: Change from Baseline (Day 1) to Week 26 in left ventricular ejection fraction

    Time frame: 26 weeks

  5. Part 1 and 2: Change from Baseline (Day 1) to Week 26 in ventilatory efficiency

    Time frame: 26 weeks

  6. Part 1 and 2: Change from Baseline (Day 1) to Week 26 in Kansas City Cardiomyopathy Questionnare (KCCQ-23) Clinical Summary Score

    All scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.

    Time frame: 26 weeks

  7. Part 1: Proportion of participants from Baseline (Day 1) to Week 26 who achieve at least a one-class improvement in New York Heart Association (NYHA) class

    NYHA is a system used to categorize the severity of heart failure symptoms based on a patient's functional capacity, where 1 indicates no symptoms or limitations and 4 indicates symptoms present at rest.

    Time frame: 26 weeks

  8. Part 2: Change from Baseline (Day 1) to Week 26 in left atrial function index

    Time frame: 26 weeks

  9. Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in the responder subgroup

    Time frame: 26 weeks

  10. Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in overall population

    Time frame: 26 weeks

  11. Part 1 and 2: Change from Baseline (Day 1) to Week 26 in left ventricular global longitudinal strain

    Time frame: 26 weeks

  12. Part 1 and 2: Percent change from Baseline (Day 1) to Week 26 in NT-proBNP concentrations

    Time frame: 26 weeks

  13. Part 1 and 2: Characterization of peak (Cmax) of danicamtiv

    Time frame: 20 weeks

  14. Part 1 and 2: Characterization of trough (Cmin) plasma concentrations of danicamtiv

    Time frame: 20 weeks

Other outcomes

  1. Part 1 and 2: Incidence and severity of treatment emergent adverse events, adverse events of special interest, serious adverse events and disease related events

    Time frame: 26 weeks

  2. Incidence of abnormal findings in laboratory assessments, physical examinations, 12-lead ECGs, and vital signs

    Time frame: 26 weeks

07

Study locations

72 of 79 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Sep 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Oct 7, 2025
StartActual
Feb 13, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Jan 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 11 sites changed recruiting status (11 now recruiting)
Show 11 sites
  • Stanford University Medical Center · Stanford, United StatesNot yet recruiting→Recruiting
  • Johns Hopkins Medicine · Baltimore, United StatesNot yet recruiting→Recruiting
  • Saint Luke's Mid America Heart Institute · Kansas City, United StatesNot yet recruiting→Recruiting
  • Columbia University Medical Center/ New York Presbyterian Hospital · New York, United StatesNot yet recruiting→Recruiting
  • Houston Methodist Hospital · Houston, United StatesNot yet recruiting→Recruiting
  • Jessa Ziekenhuis · Hasselt, BelgiumNot yet recruiting→Recruiting
  • Azienda Ospedaliera Universitaria Consorziale - Policlinico Bari · Bari, ItalyNot yet recruiting→Recruiting
  • Narodowy Instytut Kardiologii Stefana kardynala Wyszynskiego - Panstwowy Instytut Badawczy w Warszawie · Warsaw, PolandNot yet recruiting→Recruiting
  • Danderyds sjukhus · Stockholm, SwedenNot yet recruiting→Recruiting
  • CHRU de Tours - Hopital Trousseau · Chambray-lès-Tours, FranceNot yet recruiting→Recruiting
  • CHU Rennes - Hopital Pontchaillou · Rennes, FranceNot yet recruiting→Recruiting
Show site
  • Papworth Hospital · Cambridge, United Kingdom
across 2 updates, Oct 5, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    1 site added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • CHRU de Tours - Hopital Trousseau · Chambray-lès-Tours, FranceNot yet recruiting→Recruiting
    • CHU Rennes - Hopital Pontchaillou · Rennes, FranceNot yet recruiting→Recruiting
    Show site
    • Papworth Hospital · Cambridge, United Kingdom
  2. Oct 5, 2026
    9 sites changed recruiting status (9 now recruiting)
    Show 9 sites
    • Stanford University Medical Center · Stanford, United StatesNot yet recruiting→Recruiting
    • Johns Hopkins Medicine · Baltimore, United StatesNot yet recruiting→Recruiting
    • Saint Luke's Mid America Heart Institute · Kansas City, United StatesNot yet recruiting→Recruiting
    • Columbia University Medical Center/ New York Presbyterian Hospital · New York, United StatesNot yet recruiting→Recruiting
    • Houston Methodist Hospital · Houston, United StatesNot yet recruiting→Recruiting
    • Jessa Ziekenhuis · Hasselt, BelgiumNot yet recruiting→Recruiting
    • Azienda Ospedaliera Universitaria Consorziale - Policlinico Bari · Bari, ItalyNot yet recruiting→Recruiting
    • Narodowy Instytut Kardiologii Stefana kardynala Wyszynskiego - Panstwowy Instytut Badawczy w Warszawie · Warsaw, PolandNot yet recruiting→Recruiting
    • Danderyds sjukhus · Stockholm, SwedenNot yet recruiting→Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07210723
Lead sponsor
Kardigan, Inc.
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Feb 13, 2026
Primary completion
Sep 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Kardigan Clinical Trial Information Team
Contact
clinicaltrials@kardigan.bio
1-877-310-5135

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danicamtiv

Start the discussion